Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategySeth A. Wander, Joyce M. Slingerland|Journal of Clinical Investigation|2011Cited by 417
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Kevin Kalinsky, Seth A. Wander, Giampaolo Bianchini et al.|Journal of Clinical Oncology|2024Cited by 75
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapySeth A. Wander, Joyce M. Slingerland, Dekuang Zhao et al.|Breast Cancer Research and Treatment|2013Cited by 58
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R. Lloyd, Seth A. Wander, Komal Jhaveri et al.|Nature Reviews Clinical Oncology|2024Cited by 55
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Rachel O. Abelman, Aditya Bardia, Leif W. Ellisen et al.|Journal of Clinical Oncology|2023Cited by 53